355 related articles for article (PubMed ID: 20040311)
1. Autophagy in skeletal muscle: implications for Pompe disease.
Shea L; Raben N
Int J Clin Pharmacol Ther; 2009; 47 Suppl 1(Suppl 1):S42-7. PubMed ID: 20040311
[TBL] [Abstract][Full Text] [Related]
2. When more is less: excess and deficiency of autophagy coexist in skeletal muscle in Pompe disease.
Raben N; Baum R; Schreiner C; Takikita S; Mizushima N; Ralston E; Plotz P
Autophagy; 2009 Jan; 5(1):111-3. PubMed ID: 19001870
[TBL] [Abstract][Full Text] [Related]
3. Autophagy and lysosomes in Pompe disease.
Fukuda T; Roberts A; Ahearn M; Zaal K; Ralston E; Plotz PH; Raben N
Autophagy; 2006; 2(4):318-20. PubMed ID: 16874053
[TBL] [Abstract][Full Text] [Related]
4. Murine muscle cell models for Pompe disease and their use in studying therapeutic approaches.
Takikita S; Myerowitz R; Zaal K; Raben N; Plotz PH
Mol Genet Metab; 2009 Apr; 96(4):208-17. PubMed ID: 19167256
[TBL] [Abstract][Full Text] [Related]
5. Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy.
McCall AL; Stankov SG; Cowen G; Cloutier D; Zhang Z; Yang L; Clement N; Falk DJ; Byrne BJ
Curr Gene Ther; 2019; 19(3):197-207. PubMed ID: 31223086
[TBL] [Abstract][Full Text] [Related]
6. Gene Therapy for Pompe Disease: The Time is now.
Colella P; Mingozzi F
Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
[TBL] [Abstract][Full Text] [Related]
7. Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten.
Raben N; Wong A; Ralston E; Myerowitz R
Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):13-21. PubMed ID: 22253254
[TBL] [Abstract][Full Text] [Related]
8. Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease.
Raben N; Hill V; Shea L; Takikita S; Baum R; Mizushima N; Ralston E; Plotz P
Hum Mol Genet; 2008 Dec; 17(24):3897-908. PubMed ID: 18782848
[TBL] [Abstract][Full Text] [Related]
9. Pompe Disease: New Developments in an Old Lysosomal Storage Disorder.
Meena NK; Raben N
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32962155
[TBL] [Abstract][Full Text] [Related]
10. Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder--murine Pompe disease.
Raben N; Schreiner C; Baum R; Takikita S; Xu S; Xie T; Myerowitz R; Komatsu M; Van der Meulen JH; Nagaraju K; Ralston E; Plotz PH
Autophagy; 2010 Nov; 6(8):1078-89. PubMed ID: 20861693
[TBL] [Abstract][Full Text] [Related]
11. [The efficacy of enzyme replacement therapy in pompe disease and secondary pathology in pompe muscle "excessive autophagy" which is relevant to the therapy resistance].
Fukuda T
No To Hattatsu; 2010 Mar; 42(2):114-6. PubMed ID: 23858594
[No Abstract] [Full Text] [Related]
12. Suppression of mTORC1 activation in acid-α-glucosidase-deficient cells and mice is ameliorated by leucine supplementation.
Shemesh A; Wang Y; Yang Y; Yang GS; Johnson DE; Backer JM; Pessin JE; Zong H
Am J Physiol Regul Integr Comp Physiol; 2014 Nov; 307(10):R1251-9. PubMed ID: 25231351
[TBL] [Abstract][Full Text] [Related]
13. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
[TBL] [Abstract][Full Text] [Related]
14. Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease.
Fukuda T; Ahearn M; Roberts A; Mattaliano RJ; Zaal K; Ralston E; Plotz PH; Raben N
Mol Ther; 2006 Dec; 14(6):831-9. PubMed ID: 17008131
[TBL] [Abstract][Full Text] [Related]
15. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
[TBL] [Abstract][Full Text] [Related]
16. Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy.
Prater SN; Patel TT; Buckley AF; Mandel H; Vlodavski E; Banugaria SG; Feeney EJ; Raben N; Kishnani PS
Orphanet J Rare Dis; 2013 Jun; 8():90. PubMed ID: 23787031
[TBL] [Abstract][Full Text] [Related]
17. Lentiviral gene therapy with IGF2-tagged GAA normalizes the skeletal muscle proteome in murine Pompe disease.
Liang Q; Vlaar EC; Pijnenburg JM; Rijkers E; Demmers JAA; Vulto AG; van der Ploeg AT; van Til NP; Pijnappel WWMP
J Proteomics; 2024 Jan; 291():105037. PubMed ID: 38288553
[TBL] [Abstract][Full Text] [Related]
18. Glycogen accumulation in smooth muscle of a Pompe disease mouse model.
McCall AL; Dhindsa JS; Bailey AM; Pucci LA; Strickland LM; ElMallah MK
J Smooth Muscle Res; 2021; 57(0):8-18. PubMed ID: 33883348
[TBL] [Abstract][Full Text] [Related]
19. Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease.
Douillard-Guilloux G; Raben N; Takikita S; Ferry A; Vignaud A; Guillet-Deniau I; Favier M; Thurberg BL; Roach PJ; Caillaud C; Richard E
Hum Mol Genet; 2010 Feb; 19(4):684-96. PubMed ID: 19959526
[TBL] [Abstract][Full Text] [Related]
20. Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease.
Wang J; Zhou CJ; Khodabukus A; Tran S; Han SO; Carlson AL; Madden L; Kishnani PS; Koeberl DD; Bursac N
Commun Biol; 2021 May; 4(1):524. PubMed ID: 33953320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
